$900,000,000

TERM LOAN CREDIT AGREEMENT

** **

dated as of August 11, 2026
among

FERGUSON ENTERPRISES INC.

as the Borrower,

The Guarantors Party Hereto,

JPMorgan Chase Bank, N.A.,
as Administrative Agent

and

The Lenders Party Hereto

**JPMorgan Chase Bank, N.A.****, ****BOFA SECURITIES, INC., BARCLAYS BANK PLC,
ROYAL BANK OF CANADA, SUMITOMO MITSUI BANKING CORPORATION and
****BANK OF CHINA LIMITED, LONDON BRANCH,**
as Joint Lead Arrangers and Joint Bookrunners

TABLE OF CONTENTS

Article I DEFINITIONS AND ACCOUNTING TERMS			6
	1.01	Defined Terms	6

…

$700,000,000

** **

BRIDGE CREDIT AGREEMENT

** **

dated as of August 11, 2026
among

FERGUSON ENTERPRISES INC.

as the Borrower,

The Guarantors Party Hereto,

JPMorgan Chase Bank, N.A.,
as Administrative Agent

and

The Lenders Party Hereto

JPMorgan Chase Bank, N.A.,
as Sole Lead Arranger and Bookrunner

TABLE OF CONTENTS

Article I DEFINITIONS AND ACCOUNTING TERMS			6
	1.01	Defined Terms	6
	1.02	Other Interpretive Provisions	38

…

‌Beyond Li-ion™

SolidEnergy Systems LLC

35 Cabot Road, Woburn, MA 01801

​

Yi (Ray) LiuApril 8, 2026
512 Wyoming Avenue

Millburn, NJ

​

Re:Employment as Chief Financial Officer

​

​

Dear Ray:

​

Welcome to SES! I am pleased to confirm the terms on which you will be employed by SolidEnergy Systems LLC (the “Company”).

​

| | | |

…

****SolidEnergy Systems LLC

35 Cabot Road, Woburn, MA 01801

​

​

April 20, 2026

​

Jing Nealis

2050 Harvest Road

Pleasanton, CA 94566

​

RE: Separation Agreement

​

Dear Jing:

​

This agreement will confirm the terms of your separation from employment with SolidEnergy Systems, LLC (the “Company”).

​

1.Separation of Employment**.  **Your last date of employment with the Company will be April 27, 2026 (the “Separation Date”).  From and after the Separation Date, you shall have no authority and shall not represent yourself as an employee or agent of the Company and/or its predecessors, successors, past or present subsidiaries, affiliated companies, investors, branches or related entities. You further agree to be available to provide assistance and transitional services to your successor as Chief Financial Officer upon reasonable request to support his or her transition into the role through May 15, 2026.

​

2.COBRA; Insurance**.** Our records indicate that you are participating in the Company’s insurance coverage plans. Your coverage under United Healthcare, and Delta Dental’s PPO, and EyeMed will terminate effective April 30, 2026.  You may have a legal right, pursuant to the Consolidated Omnibus Budget Reconciliation Act (COBRA), after your Separation Date and upon timely completion of the appropriate forms, to continue at your own expense, your medical, dental, and vision insurance coverage.  The Company will provide you with timely and proper notice of your COBRA rights and any necessary forms to elect COBRA after the Separation Date.

​

…

SEVERANCE AGREEMENT

This Severance Agreement (the "Agreement") is entered into as of the 10th day of August 2026, by and between Troy W. Ingianni, an individual with a residence address of [***] (the "Executive"), and TransAct Technologies Incorporated, a Delaware corporation with a mailing address of One Hamden Center, 2319 Whitney Avenue, Suite 3B, Hamden, Connecticut 06518 (the "Company"). As used in this Agreement, the "Company" shall also include all subsidiaries of the Company, as the context requires.

*INTRODUCTION *

1.       The Company is in the business of developing, manufacturing and marketing market-specific solutions including printers, terminals, software and other products for transaction-based and other industries (the "Business").

2.       The Company desires that the Executive serve in the position of Chief Financial Officer with the Company and that the Company be able to rely upon his advice when requested as to the best interests of the Company, and its shareholders.

3.       The Board of Directors of the Company believes the Executive can best serve the Company without the distractions of personal uncertainties and risks that might be created in the event a change in control of the Company is proposed or his employment by the Company is terminated.

AGREEMENT

In consideration of the premises and mutual promises herein below set forth, the parties hereby agree as follows:

1.       Definitions. The following terms shall have the meanings indicated for the purposes of this Agreement:

…

(Signature page to Indemnification Agreement) TRULIEVE CANNABIS CORP. INDEMNIFICATION AGREEMENT This Indemnification Agreement, dated [_______], 2026, is made between Trulieve Cannabis Corp., a Delaware corporation (the “Company”), and [______________] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of talented and experienced individuals, such as Indemnitee, to serve as directors and officers of the Company and its subsidiaries and wishes to indemnify its directors and officers to the maximum extent permitted by law; WHEREAS, the Company and Indemnitee recognize that corporate litigation in general has subjected directors and officers to expensive litigation risks; WHEREAS, Section 145 (“Section 145”) of the General Corporation Law of the State of Delaware, as amended (“DGCL”), under which the Company is organized, empowers the Company to indemnify its directors and officers by agreement and to indemnify persons who serve, at the request of the Company, as the directors and officers of other corporations or enterprises, and expressly provides that the indemnification provided by Section 145 is not exclusive; WHEREAS, Section 145(g) of the DGCL allows for the purchase of director and officer liability insurance (“D&O Insurance”) by the Company, which in theory can cover asserted liabilities without regard to whether they are indemnifiable by the Company or not; WHEREAS, individuals considering service or presently serving expect to be extended market terms of indemnification commensurate with their position,

…

LENZ THERAPEUTICS, INC.

OUTSIDE DIRECTOR COMPENSATION POLICY

LENZ Therapeutics, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Directors”). This Outside Director Compensation Policy (the “Policy”) is intended to formalize the Company’s policy regarding cash compensation and grants of equity awards to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company’s 2024 Equity Incentive Plan, as amended from time to time (or if such plan no longer is in use at the time of the grant of an equity award, the meaning given such term or any similar term in the equity plan then in place under which such equity award is granted) (such applicable plan, the “Plan”). Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity awards and cash and other compensation such Outside Director receives under this Policy.

1.Cash Compensation

a.Annual Cash Retainers for Service as Outside Director. Each Outside Director will be paid a cash retainer of $50,000 per year. There are no per-meeting attendance fees for attending Board meetings or meetings of any committee of the Board.

…

CONSULTING AGREEMENT

Effective April 21, 2026 (“Effective Date”), Dr. Eli Wallace (“Consultant”) and BridgeBio Oncology Therapeutics, Inc. (“Company”) agree as follows:

1.

Services; No Violation of Rights or Obligations. Consultant agrees to undertake and complete the Services (as defined in Exhibit A) in accordance with and on the schedule specified in Attachment A. The only consideration due Consultant regarding the subject matter of this Agreement is set forth on Attachment A. Unless otherwise specifically agreed upon by Company in writing (and notwithstanding any other provision of this Agreement), all activity relating to Services will be performed by and only by Consultant or by employees of Consultant and only those such employees who have been approved in writing in advance by Company.Consultant agrees that it will not (and will not permit others to) violate any agreement with or rights of any third party or, except as expressly authorized by Company in writing hereafter, use or disclose at any time Consultant’s own or any third party’s confidential information or intellectual property in connection with the Services or otherwise for or on behalf of Company.

2.

Ownership Rights; Proprietary Information; Publicity.

a.

…

May 11, 2026

Idan Elmelech

Re: Employment Agreement and Executive Severance Plan Participation Agreement

Dear Idan:

This agreement confirms the terms of your employment as Chief Operating Officer of the Company commencing as of the Effective Date (as defined below). If executed, this Employment Agreement and Executive Severance Plan Participation Agreement (the “Agreement”) shall become effective retroactively as of April 20, 2026 (the “Effective Date”). Except with respect to the Equity Documents, the Restrictive Covenants Agreement (as defined below) and the Severance Plan (each as defined below), this Agreement supersedes in all respects all prior agreements between you and BridgeBio Oncology Therapeutics, Inc. (the “Company”) (or its predecessor(s)) regarding the subject matter herein, including without limitation (i) the Offer Letter, dated April 16, 2024, by and between you and the Company (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.

1.

…

May 11, 2026

Dr. Pedro Beltran

Re: Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement

Dear Pedro:

This agreement confirms the terms of your employment as Chief Executive Officer of the Company commencing as of the Effective Date (as defined below). If executed, this Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement (the “Agreement”) shall become effective retroactively as of April 20, 2026 (the “Effective Date”). Except with respect to the Equity Documents, the Restrictive Covenants Agreement (as defined below) and the Severance Plan (each as defined below), this Agreement supersedes in all respects all prior agreements between you and BridgeBio Oncology Therapeutics, Inc. (the “Company”) (or its predecessor(s)) regarding the subject matter herein, including without limitation (i) the Employment Agreement, dated August 11, 2025, by and between you and the Company (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.

1.

…

AMENDMENT NO. 9

TO TRANSITION SERVICES AGREEMENT

This Amendment No. 9 (“Amendment No. 9”) to the Agreement (as defined below) is entered into as of June 23, 2026 (the “Effective Date”) by and among BridgeBio Services Inc., a Delaware corporation (“BBIO”), TheRas, Inc., a Delaware corporation (“BBOT”), BridgeBio Pharma LLC (“BBP LLC”), and BridgeBio Oncology Therapeutics, Inc. (“PubCo”). BBIO, BBOT, BBP LLC and PubCo may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement (as defined below) to the extent defined therein.

WHEREAS, BBIO and BBOT entered into that certain Transition Services Agreement, dated April 30, 2024, as amended (the “Agreement”);

WHEREAS, the Parties now wish to further amend the Agreement to update the Service Schedule on Exhibit A thereto;

NOW, THEREFORE, in consideration of the covenants, conditions and undertakings hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.

Amendment to Service Schedule. Exhibit A of the Agreement is hereby deleted in its entirety and replaced with the following new Exhibit A attached hereto.

2.

…

IMMUNOME, INC

2024 INDUCEMENT PLAN

EFFECTIVE AS OF: OCTOBER 3, 2024

AMENDED BY THE COMPENSATION COMMITTEE AS OF: MAY 8, 2025 and MAY 12, 2026

1. GENERAL.

(a) Eligible Award Recipients.The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a bona fide period of non-employment. Persons eligible to receive grants of Awards under this Plan are referred to in this Plan as “Eligible Employees.” These Awards must be approved by either a majority of the Company’s “Independent Directors” (as such term is defined in Nasdaq Marketplace Rule 5605(a)(2)) (“Independent Directors”) or the Company’s compensation committee, provided such committee is comprised solely of Independent Directors (the “Independent Compensation Committee”) in order to comply with the exemption from the stockholder approval requirement for “inducement grants” provided under Rule 5635(c)(4) of the Nasdaq Marketplace Rules. Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 (together with any analogous rules or guidance effective after the date hereof) are referred to in this Plan as the “Inducement Award Rules.”

…